RAPT has 36-month beta value of -0.11. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for RAPT is 8.62M, and currently, short sellers hold a 8.71% ratio of that float. The average trading volume of RAPT on June 26, 2025 was 107.99K shares.
RAPT) stock’s latest price update
RAPT Therapeutics Inc (NASDAQ: RAPT)’s stock price has plunge by 16.30relation to previous closing price of 8.22. Nevertheless, the company has seen a 21.94% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-23 that SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appointed as a member of the Nominating and Corporate Governance Committee of the Board. The company’s lead product candidate RPT904, is a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E (“IgE”), a key driver of several allergic diseases. RPT904 is currently completing Phase 2 trials in chronic spontaneous urticaria and asthma, and RAPT plans to initiate a Phase 2 clinical trial for food allergy later this year.
RAPT’s Market Performance
RAPT Therapeutics Inc (RAPT) has experienced a 21.94% rise in stock performance for the past week, with a -2.85% drop in the past month, and a -23.40% drop in the past quarter. The volatility ratio for the week is 7.46%, and the volatility levels for the past 30 days are at 6.32% for RAPT. The simple moving average for the last 20 days is 16.23% for RAPT stock, with a simple moving average of -9.21% for the last 200 days.
Analysts’ Opinion of RAPT
Many brokerage firms have already submitted their reports for RAPT stocks, with H.C. Wainwright repeating the rating for RAPT by listing it as a “Buy.” The predicted price for RAPT in the upcoming period, according to H.C. Wainwright is $6 based on the research report published on May 22, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see RAPT reach a price target of $10. The rating they have provided for RAPT stocks is “Buy” according to the report published on December 26th, 2024.
Stifel gave a rating of “Hold” to RAPT, setting the target price at $2 in the report published on November 13th of the previous year.
RAPT Trading at 27.72% from the 50-Day Moving Average
After a stumble in the market that brought RAPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.76% of loss for the given period.
Stock Fundamentals for RAPT
The total capital return value is set at -0.69. Equity return is now at value -75.60, with -67.86 for asset returns.
Based on RAPT Therapeutics Inc (RAPT), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -28.33.
Currently, EBITDA for the company is -126.33 million with net debt to EBITDA at 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.11.
Conclusion
To put it simply, RAPT Therapeutics Inc (RAPT) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
